SG11201703806XA - Method for treating cancer - Google Patents

Method for treating cancer

Info

Publication number: SG11201703806XA
Authority: SG; Singapore
Prior art keywords: treating cancer; cancer; treating
Prior art date: 2014-11-17

Application number

SG11201703806XA

Other languages

English (en)

Inventor

Heike Keilhack

Brett Truitt

Yuta Suzuki

Tsukasa Murase

Futoshi Shikata

Original Assignee

Epizyme Inc

Eisai R&D Man Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-17

Filing date

2015-11-17

Publication date

2017-06-29

2015-11-17 Application filed by Epizyme Inc, Eisai R&D Man Co Ltd filed Critical Epizyme Inc

2017-06-29 Publication of SG11201703806XA publication Critical patent/SG11201703806XA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SG11201703806XA 2014-11-17 2015-11-17 Method for treating cancer SG11201703806XA (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201462080985P	2014-11-17	2014-11-17
US201562166572P	2015-05-26	2015-05-26
US201562251903P	2015-11-06	2015-11-06
PCT/US2015/061194 WO2016081523A1 (en)	2014-11-17	2015-11-17	Method for treating cancer

Publications (1)

Publication Number	Publication Date
SG11201703806XA true SG11201703806XA (en)	2017-06-29

Family

ID=56014476

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201703806XA SG11201703806XA (en)	2014-11-17	2015-11-17	Method for treating cancer

Country Status (21)

Country	Link
US (2)	US10786511B2 (fi)
EP (2)	EP4272742A1 (fi)
JP (3)	JP6829684B2 (fi)
KR (3)	KR102338802B1 (fi)
CN (2)	CN116650500A (fi)
AU (3)	AU2015350108B2 (fi)
BR (1)	BR112017010166A2 (fi)
CA (1)	CA2967664A1 (fi)
DK (1)	DK3220916T3 (fi)
EA (1)	EA201791095A1 (fi)
ES (1)	ES2947819T3 (fi)
FI (1)	FI3220916T3 (fi)
HU (1)	HUE062159T2 (fi)
IL (3)	IL296080B2 (fi)
LT (1)	LT3220916T (fi)
MX (2)	MX2017006089A (fi)
PL (1)	PL3220916T3 (fi)
PT (1)	PT3220916T (fi)
SG (1)	SG11201703806XA (fi)
SI (1)	SI3220916T1 (fi)
WO (1)	WO2016081523A1 (fi)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2863996T3 (es)	2013-12-06	2021-10-13	Epizyme Inc	Terapia de combinación para el tratamiento del cáncer
PT3157527T (pt)	2014-06-17	2023-06-30	Eisai R&D Man Co Ltd	Inibidores de ezh2 para tratamento de linfoma
MX2017006089A (es)	2014-11-17	2017-12-11	Epizyme Inc	Metodo para tratar el cancer.
WO2016172199A1 (en)	2015-04-20	2016-10-27	Epizyme, Inc.	Combination therapy for treating cancer
CN107635965A (zh)	2015-06-10	2018-01-26	Epizyme股份有限公司	用于治疗淋巴瘤的ezh2抑制剂
WO2017035234A1 (en)	2015-08-24	2017-03-02	Epizyme, Inc.	Method for treating cancer
WO2017132518A1 (en)	2016-01-29	2017-08-03	Epizyme, Inc.	Combination therapy for treating cancer
WO2017210395A1 (en)	2016-06-01	2017-12-07	Epizyme, Inc.	Use of ezh2 inhibitors for treating cancer
MA45406A (fr)	2016-06-17	2019-04-24	Epizyme Inc	Inhibiteurs d'ezh2 pour traiter le cancer
BR112019014924A2 (pt)	2017-01-19	2020-03-31	St. Marianna University School Of Medicine	Composição farmacêutica usada para o tratamento de mielopatia associada ao htlv-1
WO2018183885A1 (en)	2017-03-31	2018-10-04	Epizyme, Inc.	Combination therapy for treating cancer
CN110944628A (zh)	2017-06-02	2020-03-31	Epizyme股份有限公司	使用ezh2抑制剂治疗癌症
EP3678663A4 (en)	2017-09-05	2021-06-02	Epizyme, Inc.	POLYTHERAPY FOR CANCER TREATMENT
IL294108A (en) *	2019-12-20	2022-08-01	Epizyme Inc	Crystalline salt of hydrobromide of ezh2 inhibitor, its preparation and effective pharmaceutical composition for cancer treatment
JP2022167451A (ja)	2021-04-23	2022-11-04	日立Astemo株式会社	情報処理装置、情報処理方法、プログラムおよび記憶媒体
WO2023159124A2 (en) *	2022-02-17	2023-08-24	Memorial Sloan-Kettering Cancer Center	Methods for overcoming tazemetostat-resistance in cancer patients
TW202400140A (zh)	2022-04-27	2024-01-01	日商第一三共股份有限公司	抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en)	2001-08-02	2007-06-12	Regents Of The University Of Michigan	Expression profile of prostate cancer
US20070026064A1 (en) *	2005-07-29	2007-02-01	Yoder Steven L	Pharmaceutical dosage forms having watermark-type identification and authentication inditia
US20100278921A1 (en) *	2009-04-30	2010-11-04	Fischer Cristina M	Solid oral formulation of abt-263
CA3176977A1 (en)	2010-09-10	2012-03-15	Epizyme, Inc.	Inhibitors of human ezh2, and methods of use thereof
US9175331B2 (en)	2010-09-10	2015-11-03	Epizyme, Inc.	Inhibitors of human EZH2, and methods of use thereof
WO2012097222A1 (en) *	2011-01-14	2012-07-19	Bristol-Myers Squibb Company	High drug load tablet formulation of brivanib alaninate
EP2681216B1 (en)	2011-02-28	2017-09-27	Epizyme, Inc.	Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar)	2011-04-13	2019-10-20	Epizyme Inc	مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh)	2011-04-13	2017-09-11	雅酶股份有限公司	經取代之苯化合物
KR20230145531A (ko) *	2012-03-12	2023-10-17	에피자임, 인코포레이티드	인간 ｅｚｈ2의 억제제 및 이의 사용 방법
BR112014025506B1 (pt) *	2012-04-13	2024-02-06	Epizyme, Inc	Composição que compreende composto inibidor de ezh2, uso terapêutico da mesma e método in vitro de inibição da proliferação de células de câncer
SI2836491T1 (sl)	2012-04-13	2017-06-30	Epizyme, Inc.	Oblike soli inhibitorja humane histon metiltransferaze EZH2
HUE046790T2 (hu) *	2012-10-15	2020-03-30	Epizyme Inc	A rák kezelésének módszerei
KR102057366B1 (ko)	2012-10-15	2019-12-18	에피자임, 인코포레이티드	치환된 벤젠 화합물
WO2014100080A1 (en) *	2012-12-19	2014-06-26	Glaxosmithkline Llc	Combination
AU2013361079B2 (en)	2012-12-21	2018-07-26	Epizyme, Inc.	1,4-pyridone bicyclic heteroaryl compounds
CA2894216A1 (en)	2012-12-21	2014-06-26	Epizyme, Inc.	1,4-pyridone compounds
US9776996B2 (en)	2013-03-15	2017-10-03	Epizyme, Inc.	Substituted 6,5-fused bicyclic heteroaryl compounds
AU2014254392B2 (en)	2013-03-15	2018-05-24	Epizyme, Inc.	Substituted benzene compounds
WO2015010049A1 (en)	2013-07-19	2015-01-22	Epizyme, Inc.	Substituted benzene compounds
EP3057962B1 (en) *	2013-10-16	2023-10-18	Epizyme, Inc.	Hydrochloride salt form for ezh2 inhibition
JP2016533364A (ja) *	2013-10-18	2016-10-27	エピザイム，インコーポレイティド	癌を処置する方法
ES2863996T3 (es)	2013-12-06	2021-10-13	Epizyme Inc	Terapia de combinación para el tratamiento del cáncer
PT3157527T (pt) *	2014-06-17	2023-06-30	Eisai R&D Man Co Ltd	Inibidores de ezh2 para tratamento de linfoma
EP3160940A4 (en)	2014-06-25	2018-05-02	Epizyme, Inc.	Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
WO2016061507A1 (en)	2014-10-16	2016-04-21	Epizyme, Inc.	Method for treating cancer
MX2017006089A (es)	2014-11-17	2017-12-11	Epizyme Inc	Metodo para tratar el cancer.
CN107635965A (zh) *	2015-06-10	2018-01-26	Epizyme股份有限公司	用于治疗淋巴瘤的ezh2抑制剂
MA45406A (fr) *	2016-06-17	2019-04-24	Epizyme Inc	Inhibiteurs d'ezh2 pour traiter le cancer

2015
- 2015-11-17 MX MX2017006089A patent/MX2017006089A/es unknown
- 2015-11-17 EP EP23168326.9A patent/EP4272742A1/en active Pending
- 2015-11-17 FI FIEP15860676.4T patent/FI3220916T3/fi active
- 2015-11-17 LT LTEPPCT/US2015/061194T patent/LT3220916T/lt unknown
- 2015-11-17 ES ES15860676T patent/ES2947819T3/es active Active
- 2015-11-17 EA EA201791095A patent/EA201791095A1/ru unknown
- 2015-11-17 KR KR1020177016377A patent/KR102338802B1/ko active IP Right Grant
- 2015-11-17 KR KR1020247007271A patent/KR20240035908A/ko not_active Application Discontinuation
- 2015-11-17 KR KR1020217040314A patent/KR102644844B1/ko active IP Right Grant
- 2015-11-17 AU AU2015350108A patent/AU2015350108B2/en active Active
- 2015-11-17 EP EP15860676.4A patent/EP3220916B1/en active Active
- 2015-11-17 US US15/527,375 patent/US10786511B2/en active Active
- 2015-11-17 BR BR112017010166A patent/BR112017010166A2/pt not_active Application Discontinuation
- 2015-11-17 WO PCT/US2015/061194 patent/WO2016081523A1/en active Application Filing
- 2015-11-17 CA CA2967664A patent/CA2967664A1/en active Pending
- 2015-11-17 CN CN202310518396.8A patent/CN116650500A/zh active Pending
- 2015-11-17 PL PL15860676.4T patent/PL3220916T3/pl unknown
- 2015-11-17 IL IL296080A patent/IL296080B2/en unknown
- 2015-11-17 CN CN201580063476.2A patent/CN107249591B/zh active Active
- 2015-11-17 JP JP2017526088A patent/JP6829684B2/ja active Active
- 2015-11-17 PT PT158606764T patent/PT3220916T/pt unknown
- 2015-11-17 SI SI201531949T patent/SI3220916T1/sl unknown
- 2015-11-17 DK DK15860676.4T patent/DK3220916T3/da active
- 2015-11-17 HU HUE15860676A patent/HUE062159T2/hu unknown
- 2015-11-17 SG SG11201703806XA patent/SG11201703806XA/en unknown
2017
- 2017-05-09 IL IL252182A patent/IL252182B2/en unknown
- 2017-05-09 MX MX2021006734A patent/MX2021006734A/es unknown
2020
- 2020-08-20 US US16/998,144 patent/US20210060030A1/en active Pending
2021
- 2021-01-22 JP JP2021008382A patent/JP2021073241A/ja active Pending
- 2021-07-06 AU AU2021204706A patent/AU2021204706B2/en active Active
2023
- 2023-02-24 JP JP2023027585A patent/JP7485810B2/ja active Active
- 2023-07-04 IL IL304252A patent/IL304252A/en unknown
2024
- 2024-02-22 AU AU2024201171A patent/AU2024201171A1/en active Pending

Also Published As

Publication number	Publication date
AU2015350108B2 (en)	2021-04-08
CN107249591A (zh)	2017-10-13
WO2016081523A1 (en)	2016-05-26
NZ768247A (en)	2024-05-31
EP3220916B1 (en)	2023-04-19
HUE062159T2 (hu)	2023-10-28
JP2021073241A (ja)	2021-05-13
EP4272742A1 (en)	2023-11-08
CA2967664A1 (en)	2016-05-26
CN116650500A (zh)	2023-08-29
KR102644844B1 (ko)	2024-03-07
IL304252A (en)	2023-09-01
KR20210156840A (ko)	2021-12-27
CN107249591B (zh)	2024-01-30
KR102338802B1 (ko)	2021-12-14
BR112017010166A2 (pt)	2018-02-14
AU2021204706A1 (en)	2021-07-29
AU2021204706B2 (en)	2023-11-23
PL3220916T3 (pl)	2023-08-14
JP2017537899A (ja)	2017-12-21
EP3220916A4 (en)	2018-07-11
FI3220916T3 (fi)	2023-06-19
MX2021006734A (es)	2021-07-02
SI3220916T1 (sl)	2023-09-29
IL296080B1 (en)	2023-08-01
KR20240035908A (ko)	2024-03-18
IL296080B2 (en)	2023-12-01
NZ731696A (en)	2024-03-22
AU2024201171A1 (en)	2024-03-14
MX2017006089A (es)	2017-12-11
US10786511B2 (en)	2020-09-29
IL252182B2 (en)	2023-02-01
JP6829684B2 (ja)	2021-02-10
EP3220916A1 (en)	2017-09-27
LT3220916T (lt)	2023-07-25
JP2023062189A (ja)	2023-05-02
IL252182A0 (en)	2017-07-31
US20210060030A1 (en)	2021-03-04
ES2947819T3 (es)	2023-08-21
JP7485810B2 (ja)	2024-05-16
IL252182B (en)	2022-10-01
AU2015350108A1 (en)	2017-05-25
DK3220916T3 (da)	2023-06-26
US20170360797A1 (en)	2017-12-21
IL296080A (en)	2022-11-01
EA201791095A1 (ru)	2017-10-31
PT3220916T (pt)	2023-06-26
KR20170103768A (ko)	2017-09-13

Publication	Publication Date	Title
IL304252A (en)	2023-09-01	Cancer treatment methods
IL289947A (en)	2022-03-01	A method for treating cancer
HK1251407A1 (zh)	2019-02-01	治療癌症的方法
ZA201706616B (en)	2021-03-31	Method for treating cancer
IL257691A (en)	2018-04-30	A method for treating cancer
EP3110509A4 (en)	2017-11-01	Method for treating cancer
HK1254258A1 (zh)	2019-07-12	使用阿吡莫德治療癌症的方法
HK1244217A1 (zh)	2018-08-03	用於治療蛋白質病的方法
SG11201607130RA (en)	2016-09-29	Combination method for treatment of cancer
HK1250944A1 (zh)	2019-01-18	用於治療癌症的方法
HK1248135A1 (zh)	2018-10-12	用於治療癌症的聯合方法
IL246558A0 (en)	2016-08-31	New methods of cancer treatment
HK1250942A1 (zh)	2019-01-18	用於治療癌症的方法
HK1250943A1 (zh)	2019-01-18	用於治療癌症的方法
ZA201608820B (en)	2019-12-18	Method for treating drug resistant cancer
SG10201508795XA (en)	2017-05-30	Method for treating cancer
HK1256371A1 (zh)	2019-09-20	用於治療腫瘤的方法